CST9L

Across TCGA pan-cancer cohorts, CST9L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CST9L data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CST9L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CST9L expression acts as an unfavorable survival marker.

ESCA, SKCM, and BLCA are the cancer types where CST9L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
SKCM	OS	Median	II,III,IV	0.569	0.846	<.001	8	view →
BLCA	DFS	Median	IV	0.077	0.476	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CST9L–ESCA (OS)

Open the ESCA breakdown →